What happened
Sahir Raoof, a former SignalFire partner and executive at two healthcare startups, announced the closing of a $27.5 million venture‑capital fund called Proximal Ventures. The fund is positioned as a first‑check vehicle that will write checks of $500,000 to $1.5 million in pre‑seed and seed rounds for companies that apply artificial intelligence to the tools, infrastructure, and services that support drug development. Raoof disclosed the fund’s backing from a mix of strategic investors and traditional venture firms, including ChronicleBio (co‑founded by former OpenAI executive Fidji Simo), SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors such as Nan Li, Zavain Dar, and Amy Abernethy, co‑founder of Highlander Health and former FDA principal deputy commissioner. Raoof described Proximal as a “first‑check fund that loves to partner with founders before incorporation to support ideation and initial GTM strategy.” The fund’s thesis is that AI can automate many service‑oriented stages of pharmaceutical development—molecule synthesis, manufacturing scale‑up, and clinical‑trial data analysis—allowing startups to deliver the same services faster and at lower cost.
The announcement appeared in a TechCrunch article on November 11, 2026, citing Raoof’s LinkedIn post and statements to the reporter. Raoof highlighted his background in business development at Iterative Health, a clinical‑trial recruitment startup, and partnership work at Flatiron Health, which was acquired by Roche for $1.9 billion in 2018. He also noted a two‑year stint as a principal at SignalFire, underscoring his experience in early‑stage investing.
Proximal’s investment strategy focuses on the pre‑seed and seed stages, with check sizes ranging from $500 k to $1.5 M. The fund’s limited partners include both AI‑focused and healthcare‑focused investors, suggesting a blend of technical and domain expertise that could help portfolio companies navigate both AI development and pharma regulatory pathways.
Raoof emphasized that the traditional view of pharma as a buyer of services rather than software is shifting. He argues that AI can automate many of those services, creating a “golden age of biology” where the bottleneck moves from scientific discovery to the systems that translate discoveries into treatments.
Source details: americanbazaaronline.com
Why it matters
The pharmaceutical industry spends billions annually on outsourced services that are traditionally labor‑intensive and slow. By targeting AI solutions that automate these service layers, Proximal Ventures could accelerate the pace at which new drugs move from discovery to market, potentially shortening development timelines by months or even years. If successful, AI‑driven service providers could lower the cost of drug development, making it more feasible for smaller biotech firms to bring therapies to market and increasing competition in a sector historically dominated by large, well‑funded players. The fund’s backing by investors with deep pharma and AI experience (e.g., ChronicleBio’s focus on AI‑enabled biomedical data analysis) adds credibility to the thesis and may help portfolio companies secure early customers in a highly regulated market. Moreover, the $27.5 million size signals a growing confidence among limited partners that AI can create tangible efficiencies in life‑science services, a trend that could spur additional capital flowing into this niche and shape the next wave of biotech entrepreneurship.
Automation of service‑oriented tasks could reduce the cost per molecule synthesized, accelerate scale‑up manufacturing simulations, and speed up clinical‑trial data analysis, directly impacting the overall time‑to‑market for new therapies.
Lower development costs may enable smaller biotech firms to pursue more ambitious or niche therapeutic areas, potentially increasing the diversity of pipelines and addressing unmet medical needs.
The fund’s composition of investors—spanning AI expertise (ChronicleBio, former OpenAI executive) and pharma experience (SignalFire, Kleiner Perkins, Bertelsmann Healthcare)—provides portfolio companies with both technical mentorship and industry connections, which are often the most significant barriers to adoption in regulated sectors.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
What should a useful AI forecast state?
What to watch next
Key indicators to monitor include the first cohort of companies Proximal backs and whether they secure pilot contracts with major pharma service providers. Early regulatory feedback on AI‑enabled drug‑development tools will also be critical, as the FDA’s stance can accelerate or hinder adoption. Additionally, the fund’s ability to attract follow‑on capital for its portfolio will reveal whether the market validates the AI‑service thesis. Finally, competitive moves by larger venture firms or corporate venture arms entering the same space could affect Proximal’s deal flow and the overall pace of AI integration in pharma services.
The first set of investments Proximal makes, including the sectors (e.g., AI‑driven molecular design, automated GMP simulation, AI‑enhanced clinical‑trial analytics) they target, will indicate how the fund interprets its thesis in practice.
Regulatory developments from the FDA or EMA concerning AI‑based tools for drug development could either accelerate market entry for portfolio companies or impose additional compliance hurdles.
Follow‑on funding rounds for Proximal‑backed startups will signal investor confidence in the AI‑service model and may attract larger strategic partners from the pharma industry.
Competitive activity from other venture firms or corporate venture arms entering the AI‑pharma services space could affect deal flow and valuation dynamics.